Clear Impact logo

Vermont Medicaid

CCS: Cervical Cancer Screening - Age 21-64 (ACS-21)

Current Value

52.1%

2021

Definition

Line Bar

Notes on Methodology

  • The target trendline in the graph above represents an accepted national benchmark percentile for Medicaid programs across the country. The value graphed historically was the national 50th percentile for comparison purposes. In 2020 (for measurement year 2019) we modified the value shown to demonstrate a target based on our actual performance.  For this measure, the target is the 50th national percentile.
  • The annual reported rate captures activity during the previous calendar year. 
  • This is a Healthcare Effectiveness & Data Information Set (HEDIS) administrative measure.
  • DVHA’s rates only include Medicaid Primary beneficiaries in HEDIS administrative measures.

Story Behind the Curve

The percentage of women ages 21 to 64 who were screened for cervical cancer using either of the following criteria:

  • Women ages 21 to 64 who had cervical cytology performed every 3 years
  • Women ages 30 to 64 who had cervical cytology/human papillomavirus (HPV) co-testing performed every 5 years

Cervical cancer can be detected in its early stages by regular screening using a Pap (cervical cytology) test.  A number of organizations, including the American College of Obstetricians and Gynecologists (ACOG), the American Medical Association (AMA) and the American Cancer Society (ACS) recommend Pap testing every one to three years for all women who have been sexually active or who are over 21.

Last updated:  August 2021

Clear Impact Suite is an easy-to-use, web-based software platform that helps your staff collaborate with external stakeholders and community partners by utilizing the combination of data collection, performance reporting, and program planning.

Scorecard Container Measure Action Actual Value Target Value Tag S A m/d/yy m/d/yyyy